Team Archive - Page 6 of 12 - NFCR

Mark Baran

Greenwich, CT Mark R. Baran currently serves on the board of AIM-HI. He is the Founder and President of Net Lease 1031, LLC which was formed to provide a customized approach for real estate investors and their advisors by leading a coordinated strategy for unique solutions in the disposition of…...

Read more

Charlie Weatherspoon

Chief Executive Officer, Integral CFO Services LLC Charlie Weatherspoon co-founded The AIM HI Translational Research Fund (AIM-HI) and serves as the chairman of the board. He is the Chief Executive Officer and Co-Founder of Integral CFO Services LLC. Integral CFO Services provides resource networking, business consulting and various management related…...

Read more

Franklin Salisbury, Jr.

Franklin Salisbury, Jr. has a background in economics, law and religion. Trained in resource economics at Yale, he has spent his career fostering innovative collaborations with experts in different fields so they might work together to address and solve acute social, healthcare and environmental issues. Bachelors of Economics, Yale University…...

Read more

Frederick W. Alt, Ph.D.

Charles A. Janeway Professor of Pediatrics & Professor of Genetics, Harvard Medical School Investigator, Howard Hughes Medical Institute, Boston Children’s Hospital Dr. Frederick Alt received his Ph.D. in Biology from Stanford University in 1977 where he worked with Robert Schimke. He moved to MIT for postdoctoral work with David Baltimore,…...

Read more

Peter K. Vogt, Ph.D.

Professor of Molecular Medicine, Scripps Research Institute Dr. Peter Vogt is a molecular biologist, virologist and geneticist. His research focuses on retroviruses and viral and cellular oncogenes. Dr. Vogt received his undergraduate education in biology at the University of Würzburg and in 1959 was awarded his Ph.D. at the University…...

Read more

Kanaga Sabapathy, Ph.D.

Head, Division of Cellular and Molecular Research, National Cancer Center Singapore Dr. Sabapathy obtained his Ph.D. in Molecular and Cellular Immunology from the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore, in 1995. After a post-doctoral stint at the Institute of Molecular Pathology in Vienna, Austria, he moved to…...

Read more

Brian Leyland-Jones, MBBS, Ph.D.

Brian Leyland-Jones BSc (1st Class Hons), MB BS, LRCP, MRCS, ECFMG, PhD, FACP, FRCPC Dr. Leyland-Jones is a past Chief of Developmental Therapeutics at the National Cancer Institute (NCI) and has served as principal, co-principal, and co-investigator on more than 100 clinical studies. While at the NCI. he coordinated the…...

Read more

Ruggero De Maria, M.D.

President, Alliance Against Cancer; Director, Institute of Pathology, Catholic University, Rome, Italy  Professor Ruggero De Maria obtained his M.D. at the University of Catania (1989) and completed his residence training in endocrinology at the University of Palermo (1994). During his postdoc at the Department of Experimental Medicine, University of Rome,…...

Read more

Webster Cavenee, Ph.D.

Director of Strategic Alliances, Ludwig Institute for Cancer Research Distinguished Professor of Medicine, University of California San Diego Dr. Cavenee did his graduate and postdoctoral training in cell biology, biochemistry and human genetics. He received his Ph.D. with honors in 1977 from the University of Kansas Medical School and then…...

Read more

Alfred Slanetz, Ph.D.

Chairman of the Board Dr. Alfred Slanetz is the founder, president, and chief executive officer of Geneius and has been since its incorporation. He also has served as a director on Geneius’s board since its incorporation in 2012. Geneius, an immuno-oncology start-up, is researching ways to help cancer patients’ immune…...

Read more